BeyondSpring's Plinabulin US Application for Chemo-Induced Neutropenia Under Review

The FDA has accepted for review BeyondSpring Inc's BYSI marketing application seeking approval for the use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
Under the priority review, the target action date is set for November 30.
Plinabulin acts as a selective immunomodulating microtubule-binding agent (SIMBA), with immune anti-cancer activities and broad activities to prevent CIN across chemotherapy and cancer types.
Price Action: BYSI shares are up 11.4% at $11.55 during the market session on the last check Tuesday.